Cisco Systems, Bristol-Meyers-Squibb, and W.W. Grainger all look to be great investments over the next 10 years.
Short-term disappointments have tossed these three stand-out stocks on the discount rack.
Can Bristol-Myers Squibb recover from this surprising "CheckMate"?
Our Fool contributors think that Bristol-Myers Squibb, 3M, and Corning could all raise their payouts soon. Here's why.
Bristol-Myers Squibb's Opdivo came up short in a key lung cancer trial, causing shares to plummet. Should investors panic?
Find out if overreactions to bad news have created some bargains in big pharma.
A high-profile failure in lung cancer patients punished Bristol-Myers Squibb's invetors and rewarded Merck & Co.'s investors.
Bristol's Opdivo fails to hit the mark in a key late-stage trial. Should investors panic?
Don't expect any big dividend hikes in the near future from these pharmaceutical stocks.
The approval of Epclusa could shake up how doctors treat hepatitis C patients with tough-to-treat genotypes of the disease.